REKA Stock Overview
Engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
Rekah Pharmaceutical Industry Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₪12.70 |
52 Week High | ₪18.87 |
52 Week Low | ₪12.27 |
Beta | -0.0064 |
1 Month Change | -4.94% |
3 Month Change | -9.09% |
1 Year Change | -26.72% |
3 Year Change | -49.38% |
5 Year Change | -48.25% |
Change since IPO | -96.37% |
Recent News & Updates
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Recent updates
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Shareholder Returns
REKA | IL Pharmaceuticals | IL Market | |
---|---|---|---|
7D | 1.1% | 4.1% | -4.4% |
1Y | -26.7% | -3.8% | 2.6% |
Return vs Industry: REKA underperformed the IL Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: REKA underperformed the IL Market which returned 2.6% over the past year.
Price Volatility
REKA volatility | |
---|---|
REKA Average Weekly Movement | 5.2% |
Pharmaceuticals Industry Average Movement | 5.4% |
Market Average Movement | 4.4% |
10% most volatile stocks in IL Market | 8.0% |
10% least volatile stocks in IL Market | 3.2% |
Stable Share Price: REKA has not had significant price volatility in the past 3 months.
Volatility Over Time: REKA's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 427 | Mordechai Elgrabli | www.rekah.co.il |
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields.
Rekah Pharmaceutical Industry Ltd. Fundamentals Summary
REKA fundamental statistics | |
---|---|
Market cap | ₪144.97m |
Earnings (TTM) | -₪6.91m |
Revenue (TTM) | ₪321.66m |
0.5x
P/S Ratio-21.0x
P/E RatioIs REKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REKA income statement (TTM) | |
---|---|
Revenue | ₪321.66m |
Cost of Revenue | ₪241.46m |
Gross Profit | ₪80.20m |
Other Expenses | ₪87.11m |
Earnings | -₪6.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.61 |
Gross Margin | 24.93% |
Net Profit Margin | -2.15% |
Debt/Equity Ratio | 90.1% |
How did REKA perform over the long term?
See historical performance and comparison